It's a sad but true statement: If you can count on the collective actions of investors to do anything, you can count on them to get it wrong time and time again.
While it would be nice to imagine that the stock market is an objective, dispassionate barometer of economic health, on the individual level, investors are frequently irrational and emotional, making decisions that aren't in their best interest. Now is no exception.
Contrarian movements
Consider: When do we see the most inflows into the market? Historically, that has been during good times, especially toward the peak of the business cycle. When the market heads south and people are scared, asset flows dry up as investors cut back their equity allocation. Unfortunately, the masses tend to move into and out of the market at exactly the wrong times, which makes for a fairly reliable contrarian indicator.
According to research from Bespoke Investment Group, consensus recommendations for stock allocation from Wall Street analysts reached a peak of 72% back in 2001, just after the peak of the stock market. As the bear market intensified, analysts dialed back their recommended exposure. Investors following that advice would have partially missed out on the rebound that began in 2003.
In the face of today's bear market, analysts are again reducing their recommended equity exposure, which has fallen to a nearly 10-year low of 58%. When the market was at similar levels back in 2003, stock allocation was at 68%. That's a very good sign for contrarians: When people are scared and running away from stocks, smart investors know to be opportunistic.
Follow the smart money
But don't just take my word for it -- some of the smartest minds in the business are trolling through the wreckage of this market turmoil and picking up some of the pieces. All-star mutual fund manager Ken Heebner turned bullish on financials last fall and built up large positions in names such as Citigroup (NYSE:C), Bank of America (NYSE:BAC), and Prudential Financial (NYSE:PRU). (Although Bloomberg just reported that Heebner has recently exited his Citigroup and Bank of America positions.)
Heebner is joined by Ron Muhlenkamp, who initiated a position in Morgan Stanley (NYSE:MS) in the fall and whose recent top holdings included beaten-down conglomerate General Electric (NYSE:GE). Fairholme manager Bruce Berkowitz has made concentrated bets on health-care picks Pfizer (NYSE:PFE) and UnitedHealth Group (NYSE:UNH).
We all know the market is a scary place right now. The odds are good, too, that we may not have reached a bottom just yet. But history has shown that when investors begin to panic and flee stocks, that's a pretty good time to be thinking of getting into equities.
That Wall Street analysts are more bearish on stocks than they've been in more than a decade is an excellent clue that a lot of that fear is already priced into the market. Excessive investor pessimism equals opportunity for those willing to tread into uncertain waters.
If you want to get a closer view of how some of the smartest people in the market are positioning their portfolios in today's market, look no further than the Fool's Champion Funds investment service. We've got the inside scoop on the best mutual funds in the business, run by some of the top names around. In an environment filled with uncertainty, more and more investors are realizing the value of having a helping hand in making their investment decisions. You can check out the service with a free 30-day trial today.
I'm not going to go out on a limb and say we've hit bottom yet, but I do believe the widespread negativity in the market is a good indication that a turning point is near. So don't cut back on equity exposure now. This is the time to stock up on investments that have great long-term prospects, so keep your eyes peeled!
Amanda Kish heads up the Fool's Champion Funds newsletter service. At the time of publication, she did not own any of the companies mentioned herein. The Motley Fool owns shares of UnitedHealth Group and Pfizer. UnitedHealth is a Motley Fool Stock Advisor and Motley Fool Inside Value selection. Pfizer is an Inside Value and Income Investor recommendation. Muhlenkamp and Fairholme are Champion Funds picks. Click here to find out more about the Fool's disclosure policy.
